Research

Hormonal

Semaglutide use is associated with a significantly higher reporting odds ratio for vision impairment and retinopathy compared to other GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, metformin, phentermine, and orlistat.

If you are taking semaglutide, be aware that there is a statistical signal for increased vision impairment reports in post-market data compared to other diabetes or weight loss drugs. This does not mean everyone will experience this, but it warrants vigilance. Ensure you have regular ophthalmological check-ups, especially if you have pre-existing diabetic retinopathy or rapid glycemic changes, and report any visual disturbances to your provider immediately.

ModerateSupportsMEDIUM confidence
Semaglutide showed significantly higher reporting of vision impairment compared to other GLP-1 receptor agonists (rOR 1.95, 95% CI 1.75–2.17, p < 0.0001), DPP-4 inhibitors (rOR 2.46, 95% CI 2.12–2.86, p < 0.0001), SGLT2 inhibitors (rOR 3.89, 95% CI 3.35–4.51, p < 0.0001), and metformin (rOR 2.23, 95% CI 1.90–2.62, p < 0.0001).
Marine Massy et al. · BMC Medicine · 2025

Why this rating

FAERS data is observational and subject to reporting bias; the paper explicitly states it cannot make causal inferences.

Source

Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data

Marine Massy et al. · BMC Medicine · 2025

DOI 10.1186/s12916-025-04031-z

cohort · n=302706Cited 10×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →